初发多发性骨髓瘤患者的核型异常与临床预后相关  

Chromosomal Abnormalities Associated with Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma

作　　者：陈海敏[1] 韦苇[1] 彭嵘[1] 石昊天 陈小玲[1] 周帆[1] Chen Hai-Min;Wei wei;PENG Rong;SHI Hao-Tian;CHEN Xiao-Ling;ZHOU Fan(Department of Hematology,Zhabei Branch of Changzheng Hospital,The Second Military Medical University,Shanghai 200070,China)

机构地区：[1]上海第二军医大学长征医院闸北分院血液科,上海200070

出　　处：《中国实验血液学杂志》2018年第5期1403-1406,共4页Journal of Experimental Hematology

基　　金：上海市科委科研计划项目(14411973400);上海市静安区医学科研青年项目(2016QN04)

摘　　要：目的:探索多发性骨髓瘤患者的核型异常在临床预后方面的评估价值。方法:回顾性分析我院2010年5月至2016年5月初发多发性骨髓瘤患者的临床资料,将对伴有t(4; 14)、t(14; 16)或17P-的患者定义为高危核型患者,其余则为标危患者。比较2组患者的疾病无进展时间(progression-free survival,PFS)和总生存时间(over survival,OS)。结果:高危核型患者有110例,标危核型患者302例。2组患者在年龄、性别、ISS分期、及治疗方案等临床特征分布上无统计学差别。高危组和标危组患者的中位OS时间分别为42(CI95%:34. 375-49. 625)和53(CI 95%:46. 310-59. 690)个月(P <0. 05),中位PFS时间分别为21(CI 95%:17. 198-24. 802)和27(CI95%:23. 406-30. 594)个月(P <0. 05)。结论:在初发多发性骨髓瘤患者中,高危核型者较标危核型者的中位PFS和OS时间缩短。Objective:To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma.Methods:The clinical and laboratory data of patients with newly diagnosed multiple myeloma(NDMM)were retrospectively analyzed in our hospital from May 2010 to May 2016.Patients who carried t(4;14),t(14;16)or 17P-(at least one of them)were defined as the patients with high-risk karyotype,whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype.PFS(progression-free survival,PFS)and OS(over all survival,OS)time was compared between the 2 groups.Results:There were 110 cases in the high-risk group,and 302 cases in the standard-risk group.The clinical characteristics,such as age,sex,ISS stage and treatment regimen etc were not statistically different between 2 groups.The median OS time of patients in the high-risk and standard-risk groups were 42 months(CI 95%:34.375-49.625 months)and 53 months(CI 95%:46.310-59.690 months)(P<0.05).The median PFS time of patients in the high-risk group and standard-risk groups was 21 months(CI95%:17.198-24.802 months)and 27 months(CI95%:23.406-30.594 months)(P<0.05).Conclusion:Among patients with newly diagnosed MM,the PFS and OS time in the patients with high-risk karyotype is shorter than that in patients with standard-risk karyotype.

关 键 词：多发性骨髓瘤 核型异常 疾病无进展时间 总生存时间 

分 类 号：R733.3[医药卫生—肿瘤]